The Board of Directors of Sanofi India Limited met on February 25, 2026, to approve the Audited Financial Results for the year ended December 31, 2025. Key actions included recommending a final dividend of ₹48 per share, bringing the total dividend for 2025 to ₹123 per share (including interim dividend). Furthermore, the Board announced significant changes in directorship, including appointments and the resignation of a Non-Executive Director.
Financial Performance and Dividend Recommendation
Sanofi India Limited announced the outcome of its Board Meeting held on Wednesday, February 25, 2026. The Board considered and approved the Audited Financial Results for the Quarter and Financial Year ended December 31, 2025, receiving an unmodified audit opinion from the Statutory Auditors, M/s Price Waterhouse & Co. Chartered Accountants LLP.
Dividend Details
The Board recommended a final dividend of ₹48 per equity share (Face Value of ₹10) for FY 2025. This is in addition to the interim dividend of ₹75 per share declared on October 29, 2025. Consequently, the total dividend for the year 2025 is ₹123 per equity share, subject to shareholder approval at the ensuing 70th Annual General Meeting (AGM).
Key Financial Highlights (Year Ended Dec 31, 2025)
The audited results indicate a Profit for the period/year of ₹3,267 Million from continuing operations. Total comprehensive income stood at ₹3,284 Million.
EPS for continuing operations was ₹141.85 for the year ended December 31, 2025.
Changes in Board of Directors
The Board also approved several changes in line with Regulation 30 of the SEBI Listing Regulations.
Director Appointments (Subject to Shareholder Approval)
- Mrs. Rajani Kesari (DIN: 02384170): Approved as an Additional Director and Independent Director for a term of Five (5) years, effective from April 01, 2026. Mrs. Kesari is a commerce graduate and former CFO of Nayara Energy Limited.
- Ms. Sudipta Chakraborty (DIN: 07166912): Approved as an Additional Director and Whole-time Director for a term of Three (3) years, effective from March 01, 2026. She will also be designated as a Key Managerial Personnel and Senior Management Personnel. Ms. Chakraborty specializes in Mergers & Acquisitions and Corporate Governance, bringing over two decades of legal experience.
Director Resignation
- Mr. Rodolfo Hrosz (DIN: 09609832): Tendered resignation as a Non-Executive Director, effective from the close of business hours on February 28, 2026, due to other pre-occupations and commitments. The Board expressed appreciation for his contribution.
Notes to Accounts Highlights
The notes accompanying the results provided context on several significant items:
- The results were reviewed by the Audit Committee on February 24, 2026, and approved by the Board on February 25, 2026.
- Financial results reflect the demerger of the Consumer Healthcare business effective June 1, 2024, which is presented as discontinued operations for FY 2024.
- Exceptional items for FY 2025 include personnel separation costs of ₹273 Million.
- The company recognized an incremental impact of ₹58 Million under Employee Benefits Expense related to the implementation of the consolidated Labour Codes notified in November 2025.
- Export sales for the year ended December 31, 2025, were lower by ₹1,481 Million due to the anticipated cessation of a contract with Zentiva.
Source: BSE
